Immunocore Holdings plc
As of Oct 22, 2026, Immunocore Holdings is in Stage 3, the topping phase, now in week 3 (since Oct 2, 2026). It closed at $32.12, 20.1% below its 52-week high and above its 200-day average, which is falling.
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune di… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IMCR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IMCR among Biotechnology204th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …204 | IMCR | Stage 3 · wk 3 | 50 | +1.8% |
Immunocore Holdings: quick answers
What stage is Immunocore Holdings in?
As of Oct 22, 2026, Immunocore Holdings (IMCR) is in Stage 3, the topping phase. It entered Stage 3 on Oct 2, 2026 and is in week 3. What the four stages mean
Is Immunocore Holdings in an uptrend?
Its uptrend has stalled. Immunocore Holdings is in Stage 3, the topping phase that follows an advance. It trades 1.0% above its 200-day average, which is falling.
How far is Immunocore Holdings from its 52-week high?
Immunocore Holdings closed at $32.12 on Oct 22, 2026, 20.1% below its 52-week high of $40.22. Its 52-week low is $27.79.
How has Immunocore Holdings performed over the past year?
As of Oct 22, 2026, Immunocore Holdings is down 4.3% over the past year and down 4.9% so far in 2026.
Which sector and industry is Immunocore Holdings in?
Immunocore Holdings is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.